Aclarion, Inc. (Nasdaq: ACON, ACONW), a healthcare technology company using biomarkers and augmented intelligence to help physicians identify the source of chronic low back pain, announced today the addition of Lanman Spinal Neurosurgery as a clinical site in its CLARITY trial. Based in Beverly Hills, Lanman Spinal Neurosurgery is a leading spine-focused private practice known for its expertise in complex spinal procedures, early adoption of advanced technologies, and high surgical volume. This marks the first private practice site in Los Angeles to join the trial, reflecting growing interest in integrating Nociscan into real-world clinical workflows beyond academic medical centers.
The CLARITY trial (Chronic Low back pain Randomized Independent Trial studY) is a prospective, randomized, multi-center study evaluating Nociscan in 300 patients undergoing surgical treatment (fusion or total disc replacement) for discogenic low back pain. The primary endpoint is change in back pain measured on a 100mm VAS Back at 12 months compared to baseline, with several secondary endpoints. Aclarion anticipates an initial internal data readout and public disclosure of early interim results in Q4 2026.
Dr. Todd Lanman, founder of Lanman Spinal Neurosurgery and a neurosurgeon with over 25 years of experience, emphasized the importance of precise diagnosis. “I have spent more than 25 years practicing spinal surgery in Beverly Hills, and my perspective is shaped not only by that experience, but also by having undergone multiple spine surgeries myself,” said Dr. Lanman. “We have made significant progress in moving beyond one-size-fits-all solutions for low back pain, driven by advances in technology and technique. Nociscan introduces a new layer of clarity by leveraging MR Spectroscopy to identify pain-generating discs in ways that standard MRI cannot. The CLARITY trial is particularly important because it is designed to evaluate how this technology can enhance clinical decision-making by more precisely identifying pain-generating discs. This ability to match the right procedure to the right patient is what moves the field forward.”
Ryan Bond, Chief Strategy Officer of Aclarion, highlighted the significance of private practice involvement. “Private practice spine surgeons play a critical role in treating the majority of patients suffering from chronic low back pain, and the inclusion of Lanman Spinal Neurosurgery reflects the growing demand for more precise, data-driven tools in everyday clinical practice,” said Bond. “Dr. Lanman is widely recognized for his commitment to innovation and patient-centered care, and we are excited to partner with his team as we continue to expand CLARITY and generate the high-quality evidence needed to advance Nociscan.”
Chronic low back pain affects approximately 266 million people worldwide. Aclarion’s Nociscan is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. It quantifies chemical biomarkers associated with disc pain, and when used with other diagnostic tools, Nociscan provides critical insights into the location of pain, demonstrating a 97% surgical success rate when all Nociscan-positive discs are treated. For more information about CLARITY, visit the trial website.
